





















### References

- Rakvåg, T. T., et al. (2008). "Genetic variation in the Catechol-O-Methyltransferase (COMT) gene and morphine requirements in cancer patients with pain." [Molecular Pain](#) **4**(1): 64.
- Ross, J. R., et al. (2008). "Genetic variation and response to morphine in cancer patients: catechol-o-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects." [Cancer](#) **112**(6): 1390.
- Sadhasivam, S. and Chidambaran, V. (2012). "Pharmacogenomics of opioids and perioperative pain management." [Pharmacogenomics](#) **13**(15): 1719.
- Smith, M. T. and Muralidharan, A. (2012). "Pharmacogenetics of pain and analgesia." [Clinical genetics](#) **82**(4): 321.
- Somogyi, A. A., et al. (2007). "Pharmacogenetics of opioids." [Clinical pharmacology and therapeutics](#) **81**(3): 429.
- Webster, L. R. (2008). "Pharmacogenetics in pain management: the clinical need." [Clinics in laboratory medicine](#) **28**(4): 569.
- Zanger, U. M., et al. (2008). "Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation." [Analytical and Bioanalytical Chemistry](#) **392**(6): 1093.